ArdorComm Media News Network
March 9, 2026
In a major medical breakthrough, Japan has approved pioneering stem-cell therapies for Parkinson’s disease and severe heart failure, marking the first time such treatments using induced pluripotent stem (iPS) cells will be commercially available. The therapies could begin reaching patients within months, according to reports and company statements.
Pharmaceutical company Sumitomo Pharma announced that it has received approval to manufacture and sell Amchepry, a treatment designed to transplant stem cells into a patient’s brain to help manage Parkinson’s disease. The therapy aims to replace lost dopamine-producing cells, which are responsible for many of the motor symptoms associated with the condition.
Meanwhile, Japan’s health ministry has also approved ReHeart, a treatment developed by medical startup Cuorips. The therapy uses sheets of heart muscle cells that can help regenerate blood vessels and improve heart function in patients suffering from severe heart failure.
These therapies are based on groundbreaking research by Japanese scientist Shinya Yamanaka, who received the Nobel Prize in Physiology or Medicine in 2012 for discovering iPS cells—cells that can develop into almost any type of cell in the human body.
Japan’s health minister Kenichiro Ueno said the government aims to ensure the treatments become available to patients as quickly as possible. “I hope this will bring relief to patients not only in Japan but around the world,” he said during a press briefing.
According to the company, Amchepry has been granted conditional and time-limited approval, allowing faster access for patients while further data on safety and effectiveness continues to be gathered. This system is designed to accelerate the availability of innovative regenerative therapies.
Clinical trials conducted by researchers at Kyoto University tested the treatment on seven Parkinson’s patients aged between 50 and 69. Each participant received either five million or ten million stem-cell-derived dopamine precursor cells implanted in both sides of the brain.
The patients were monitored for two years, and the study reported no serious side effects. Four of the participants showed noticeable improvements in their symptoms.
Parkinson’s disease is a progressive neurological disorder that affects movement and can cause tremors, stiffness, and difficulty with coordination. According to the Parkinson’s Foundation, around 10 million people worldwide live with the condition. Current treatments mainly manage symptoms but do not stop or reverse the disease.
The use of iPS cells—created by reprogramming mature cells back into a versatile, stem-like state—has become one of the most promising areas in regenerative medicine. Japan’s approval of these therapies marks a significant step toward translating this research into real-world medical treatment.
Source: AFP